Your cart is empty.
CORONAVIRUS Library

CORONAVIRUS Library

Files to download
Preferred format
Desirable size of the custom library selection
Number of compounds
Amount
Volume
uL
Description

Outbreak of coronavirus disease (COVID-19) was first reported from Wuhan, China, on 31 December 2019.

Coronaviruses (CoV) are a large family of viruses that cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). A novel coronavirus (nCoV) is a new strain that has not been previously identified in humans.

Coronaviruses are zoonotic, meaning they are transmitted between animals and people. Detailed investigations found that SARS-CoV was transmitted from civet cats to humans and MERS-CoV from dromedary camels to humans. Several known coronaviruses are circulating in animals that have not yet infected humans.

ChemDiv Virtual Screening Methodology
Swiss Prot Protein Targets and PDB X Ray Structure Search: ACE2, PLpro , 3CLP
Training Sets ChEMBL 25, PubMed, Current Patent Literature (CAS, Integrity)
Machine Learning Data Curation:
a) KNIME/ RDKit , kNN classifier, Distance in BitVector Cosine Space, FCFP12 (10,240 bit) fingerprints
b) Hybrid 2D QSAR/Fingerprint Model Kernel Chemical Classification/Regression (kcc)
3D Shape Similarity
Virtual Screening :
APF®MolSoft , Lam et al J. Comp Aided. Mol. Design (2017, 2018 & 2019); APF Totrov Chem Biol Drug Des. (2008)
Structure-Based (Ligands, Fragments, Covalent Fragments) Docking / Virtual Screening
a) Multiple Receptor Conformation (MRC) 4D Docking; ICM Pro MolSoft , Bottegoni et al (2009) J. Med. Chem. 52:397
b) Ligand Biased Ensemble receptor Docking ( LigBEnD ); ICM Pro MolSoft , Lam et al J. Comp Aided. Mol. Design (
REOS, MedChem & PAINS Filters – Removal of reactive, toxic, promiscuous, and other undesirable structural motifs
Diversity Picking (Tanimoto): RDKit implementation of the MaxMin algorithm Ashton, M. et. al., Quant. Struct. Act. Relat ., 2002, 21, 598 604.

Publications
1. J. Med. Chem. 2020, ASAP:February 11, Alpha ketoamides as broad spectrum inhibitors of coronavirus and enterovirus replication Structure based design, synthesis, and activity assessment. Zhang L, Lin D, Kusov Y, […], Hilgenfeld R. doi.org:10.1021/acs.jmedchem.9b01828

2. Nucleic Acids Research 2019, 47(12):6538 6550, Delicate structural coordination of the Severe Acute Respiratory Syndrome coronavirus Nsp13 upon ATP hydrolysis. Jia Z, Yan L, Ren Z, […], Rao Z. doi.org:10.1093/nar/gkz409

3. Nat. Commun . 2019, 10:2342, Structure of the SARS CoV nsp12 polymerase bound to nsp7 and nsp8 co factors. Kirchdoerfer RN, Ward AB. doi.org:10.1038/s41467 019 10280 3

4. J. Biol. Chem. 2004, 279: 17996 18007, ACE2 X ray structures reveal a large hinge bending motion important for inhibitor binding and catalysis. Towler P, Staker B, Prasad SG, […], Pantoliano MW. doi:10.1074/jbc.M311191200

5. Expert Rev. Anti. Infect. Ther . 2006, 4(2):291 302, Potential antivirals and antiviral strategies against SARS coronavirus infections. De Clercq E. doi:10.1586/14787210.4.2.291

6. FEBS J. 2014, 281(18):4085 4096, From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. Hilgenfeld R. doi:10.1111/febs.12936

7. Bioorg . Med. Chem. 2015, 23(4):876 890. Fused ring structure of decahydroisoquinolin as a novel scaffold for SARS 3CL protease inhibitors. Shimamoto Y, Hattori Y, Kobayashi K, […], Akaji K. doi : 10.1016/j.bmc.2014.12.028

8. Biopolymers 2016,106(4):391 403. Structural basis for the development of SARS 3CL protease inhibitors from a peptide mimic to an aza decaline scaffold. Teruya K, Hattori Y, Shimamoto Y, […], Akaji K. doi : 10.1002/bip.22773

9. Bioorg . Med. Chem. 2019, 27(2):425 435. Evaluation of a non prime site substituent and warheads combined with a decahydroisoquinolin scaffold as a SARS 3CL protease inhibitor. Ohnishi K, Hattori Y, Kobayashi K, Akaji K. doi : 10.1016/j.bmc.2018.12.019

X
X
Send a message
Request a call

Your Name*

Your E-mail*

Company*

Type in your message here…*
* Required fields

By submitting this form you confirm that you have read and accepted our privacy policy. Your data will be used exclusively for this purpose.


Your Name*

Your Phone*

Company*

* Required fields

By submitting this form you confirm that you have read and accepted our privacy policy. Your data will be used exclusively for this purpose.